CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib

The targeted treatment of advanced non-small cell lung cancer (NSCLC) harboring genomic rearrangement of ALK is a paradigm for personalized oncology. More than 15 different ALK fusion partners have been discovered in NSCLC patients. Most of these ALK fusions responded well to the ALK inhibitor crizo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Biol Ther
Autors principals: Du, Xue, Shao, Yun, Gao, Hongjun, Zhang, Xueli, Zhang, Han, Ban, Yi, Qin, Haifeng, Tai, Yanhong
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2018
Matèries:
Bedside to Bench Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6301797/
https://ncbi.nlm.nih.gov/pubmed/30273505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1480282
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars